Japan PPI inflation slips to 11-mth low in July
Investing.com -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company focused on early cancer detection, saw its shares fall 3.3% after reporting second quarter 2025 revenue that missed analyst expectations, despite posting a narrower-than-expected loss.
The cancer detection company reported total revenue of $35.5 million for the second quarter, falling short of analyst estimates of $36.9 million, though representing an 11% increase YoY. Galleri test revenue, which makes up the majority of the company’s business, grew 22% YoY to $34.4 million. GRAIL posted a quarterly loss of $3.18 per share, better than the analyst forecast of a $3.64 loss.
"We are pleased with Galleri’s growing uptake in the U.S., with more than 45,000 Galleri tests sold in the second quarter, as we continue to drive provider and patient awareness of the MCED opportunity and Galleri’s ability to detect cancer earlier, when it is more amenable to treatment," said Bob Ragusa, Chief Executive Officer at GRAIL.
The company’s net loss for the quarter was $114.0 million, which included a $28.0 million impairment of Illumina (NASDAQ:ILMN) acquisition-related intangible assets. This represents a significant improvement from the $1.5 billion loss in the same quarter last year, which had included $1.42 billion in Illumina acquisition-related impairments.
GRAIL recently announced positive top-line results from its PATHFINDER 2 study, showing that adding the Galleri test to standard care screening substantially increased cancer detection rates compared to the first PATHFINDER study. The company plans to submit detailed results for presentation at the European Society for Medical (TASE:BLWV) Oncology Congress in October.
As of June 30, GRAIL maintained a cash position of $606.1 million in cash, cash equivalents, restricted cash, and short-term marketable securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.